Articles related to INCRETIN THERAPY

In a 794-patient randomized trial, early-stage type 2 diabetes patients uncontrolled on metformin who received tirzepatide achieved nearly twice the HbA1c reduction of those on intensified conventional care at 2 years, and 60% reached normoglycemia (HbA1c <5.7%), compared to 24% in the ICC arm.

Phase 3 TRIUMPH-1 trial results for retatrutide, a triple hormone agonist targeting GIP, GLP-1, and glucagon receptors, showed up to 28.3% mean weight loss at 80 weeks and 30.3% in patients with BMI ≥35 at 104 weeks — the largest weight reduction reported in a medication trial to date, per Lilly’s press release.

Two Lilly-sponsored placebo-controlled trials found that adults who transitioned from high-dose injectable GLP-1 therapy to either oral tirzepatide (Foundayo) or a reduced 5 mg tirzepatide maintenance dose preserved most of their prior weight loss over one year, compared to substantial regain in placebo arms.

A post hoc SURPASS-CVOT analysis associated tirzepatide with fewer six-component cardiorenal events than dulaglutide in patients with type 2 diabetes and established ASCVD.